UK biopharma company Eden Biodesign wins contract with SR Pharma
Eden Biodesign, operator of the UK National Bio-manufacturing Centre, has won a major contract to supply a package of product development consultancy and biomanufacturing services to SR Pharma, a European biopharmaceutical company active in the field of RNAi therapeutics.
Eden Biodesign, operator of the UK National Bio-manufacturing Centre, has won a major contract to supply a package of product development consultancy and biomanufacturing services to SR Pharma, a European biopharmaceutical company active in the field of RNAi therapeutics.
This is the first contract for the National Biomanufacturing Centre to be publicly announced. Eden Biodesign was appointed by the Northwest Development Agency to run the National Biomanufacturing Centre, a £34.25m initiative due to open early 2006.
Eden Biodesign will use its expertise in novel bio-pharmaceutical research to develop one of SR Pharma's innovative product technology platforms. The 12 month project consists of consultancy, including strategic development guidance and international regulatory affairs advice, followed by laboratory based biomanufacturing process development and GMP manufacturing services when the National Biomanufacturing Centre comes on line early in 2006.
Eden Biodesign specialises in overcoming technical, regulatory and logistical hurdles, speeding up biopharmaceutical development timelines and reducing cost.
Crawford Brown, ceo of Eden Biodesign, said: 'We are delighted to have the opportunity to work with SR Pharma and are convinced we will be able to add substantial clinical and commercial value to their products.'
Melvyn Davies, chief financial officer of SR Pharma, said: 'This is an important step forward for SR Pharma in accessing the relevant specialist expertise needed to assist in the product development and manufacturing and thus derive value for our shareholders through an appropriate and achievable design and development strategy.'